Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.47 |
| ▸ | FNTB | P49356 | 11/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559148 | 0.93 | FNTA (0.40) | FNTAFNTBPGGT1BACE | |
| SCHEMBL1984002 | 0.91 | FNTA (0.39) | FNTAFNTBPGGT1BACE | |
| SCHEMBL1984006 | 0.91 | FNTA (0.39) | FNTAFNTBPGGT1BACE | |
| SCHEMBL29615161 | 0.91 | ENPEP (0.41) | FNTAFNTBACE | |
| SCHEMBL28101251 | 0.89 | BACE1 (0.42) | BACE1 | |
| SCHEMBL29476103 | 0.89 | FNTA (0.40) | FNTAFNTBPGGT1BACE | |
| SCHEMBL29615112 | 0.89 | FNTA (0.40) | FNTAFNTBPGGT1BACE | |
| SCHEMBL29511053 | 0.89 | FNTA (0.40) | FNTAFNTBPGGT1BACE | |
| SCHEMBL30974548 | 0.89 | BACE1 (0.35) | FNTAFNTBBACE1ACE | |
| SCHEMBL29749072 | 0.89 | FNTA (0.38) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| CN-105492456-B | Peptide composition | 节奏制药公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | FNTA 716/4885FNTB 2340/4885PGGT1B 901/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | FNTA 4436/4885FNTB 1883/4885PGGT1B 1420/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | FNTA 716/4885FNTB 2340/4885PGGT1B 901/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | FNTA 3268/4885FNTB 3846/4885PGGT1B 4041/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | FNTA 2986/4885FNTB 3953/4885PGGT1B 2940/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | FNTA 1357/4885FNTB 2887/4885PGGT1B 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.